icon-folder.gif   Conference Reports for NATAP  
 
  51th ICAAC
Chicago, IL
September 17-20, 2011
Back grey_arrow_rt.gif
 
 
 
Detection of Baseline Resistance and HIV RNA Suppression to Week 48 in the SENSE Trial: Etravirine versus Efavirenz in Treatment Naïve Participants
 
 
  Reported by Jules Levin
(ICAAC) InterScience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, September 2011
 
A.M. Geretti, MD PhD1,2, T. Conibear, PhD3, J. Johnson, PhD4, A. Hill2, PhD, S. Marks, MD5, L. Tambuyzer, MSc6, J. Vingerhoets, PhD6.
 
1University College London Medical School, London, United Kingdom; 2Liverpool University, Liverpool, United Kingdom; 3Royal Free Hampstead NHS Trust, London, United Kingdom; 4Centers for Disease Control and Prevention, Atlanta, GA; 5Janssen, Amsterdam, Netherlands; 6Tibotec-Virco, Beerse, Belgium.
 
----------------------------------------
 
The SENSE trial: Final 48-week analysis of etravirine (ETR) versus ...
www.natap.org/2011/IAS/IAS_60.htm

The SENSE trial: Final 48-week analysis of etravirine (ETR) versus efavirenz (EFV) in treatment-naïve patients. Reported by Jules Levin 6th IAS Conference on
 
Phase 2 double-blind, randomised trial of etravirine versus efavirenz ...
www.natap.org/2011/HIV/090511_01.htm

Aug 30, 2011 - Download the PDF here AiDS: Ahead of ... Abstract Background: The SENSE Trial compared etravirinewithefavirenzin treatment-naive patients
 
-----------------------------------------
 

hcv1.gif

hcv2.gif

hcv3.gif

hcv4.gif

hcv5.gif

hcv6.gif

hcv7.gif

hcv8.gif

hcv9.gif

hcv10.gif